US2019224179A1
|
|
Decreasing expression level of proteasome subunit genes by treating a human subject with a nitroxide
|
US2019224178A1
|
|
Altering expression level of glutathione S-transferase genes by treating a human subject with a nitroxide
|
US2018078539A1
|
|
T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
|
US2018078538A1
|
|
Method of treating a human subject having a desmosome associated disorder by administering a nitroxide
|
US2018092891A1
|
|
Preventing amyloid plaque formation by treating a human subject with a nitroxide
|
WO2017200953A1
|
|
Decreasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
|
CA3056059A1
|
|
Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
|
US2017326122A1
|
|
Decreasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
|
US9700550B1
|
|
Decreasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
|
US2017273958A1
|
|
Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
|
US9744162B1
|
|
Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
|
US9579311B1
|
|
Decreasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
|
US9545398B1
|
|
Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
|
US2009209581A1
|
|
Nitroxides for use in treating or preventing immunological diseases
|
US2009042937A1
|
|
Nitroxides for use in treating or preventing amyloid-related diseases
|
US2008319014A1
|
|
Nitroxides for use in treating predisposed or at risk patients
|
US2012046314A1
|
|
Nitroxides for use in treating or preventing neoplastic disease
|
US2009062338A1
|
|
Nitroxides for use in treating or preventing cardiovascular disease
|